HC Wainwright & Co. Maintains Buy on KalVista Pharma, Lowers Price Target to $16
HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $48 to $16.
SVB Leerink Maintains Outperform on KalVista Pharma, Lowers Price Target to $30
SVB Leerink analyst Joseph Schwartz maintains KalVista Pharma (NASDAQ:KALV) with a Outperform and lowers the price target from $45 to $30.
S&P 500 Rises 100 Points; Nasdaq Up 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 250 points on Tuesday.
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.
Needham Maintains Buy on KalVista Pharma, Lowers Price Target to $24
Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $38 to $24.